FDA's goal: Shorten total approval time

For the first time, the FDA committed to reduce the time it takes to review a new drug or biologic application, a step that goes well beyond the performance measures stipulated in the Prescription Drug User Fee Act. The new policy is important because it addresses a measure that patients and sponsors really care about - the total time from submission